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Abstract
Immunological therapy of progressive tumors requires not only activation and expansion of tumor specific cytotoxic T
lymphocytes (CTLs), but also an efficient effector phase including migration of CTLs in the tumor tissue followed by
conjugation and killing of target cells. We report the application of an agent-based model to recapitulate both the effect of
a specific immunotherapy strategy against B16-melanoma in mice and the tumor progression in a generic tissue section. A
comparison of the in silico results with the in vivo experiments shows excellent agreement. We therefore use the model to
predict a critical role for CD137 expression on tumor vessel endothelium for successful therapy and other mechanistic
aspects. Experimental results are fully compatible with the model predictions. The biologically oriented in silico model
derived in this work will be used to predict treatment failure or success in other pre-clinical conditions eventually leading
new promising in vivo experiments.
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Introduction
Despite intensive research, cancer is still a leading cause of
death worldwide. Immunotherapy is a promising therapeutic
strategy for different types of cancer, but in its present form it is
often not sufficient to control tumor growth in patients. Antigen
specific cytotoxic T lymphocytes represent a crucial component of
the adaptive immune system with particular importance in the
eradication of intracellular pathogens and malignant cells[1].
Considering their prominent role in cellular immunity, there is a
comprehensible interest in targeting cytotoxic T-lymphocytes to
cancer. But even so adoptively transferred CTLs can be observed
infiltrating the tumor, their capacity to control tumor growth is still
insufficient in most patients[2]. Malignancies actively shield
themselves from immune attack. Soluble and membrane-attached
molecules whose normal function is to regulate immunity and
avoid self reactivity are cunningly perverted by tumors to permit
immune escape[3].
Tumor-infiltrating lymphocytes are rendered anergic through
the actions of co-inhibitory molecules expressed on the surface of
tumor and stroma cells. Successful immunotherapy requires
combined strategies that are able to turn-off deleterious signals
while enhancing CTLs migration and overall killing capacity[4–6].
CD137, also known as 4-1BB, is a co-stimulatory protein
expressed on activated T, NK, B-lymphocytes, dendritic cells and
tumor endothelium[7,8]. CD137 natural ligand, CD137L, is present
on the surface of activated antigen presenting cells[9]. Artificial
stimulation of this molecule with monoclonal antibodies therapeu-
tically augments the cellular immune response against tumors[10].
The mechanism of action is multilayered and includes effects on both
immune and non-immune cells (i.e. endothelial cells). These
powerful agents can be combined with adoptive T cell lymphocytes
as well as chemotherapy and other immuno-modulating agents to
achieve an enhanced anti-tumoral activity [5,11–13] and avoid
undesired side effects like the hepatotoxicity that has been recently
described under anti-CD137 high dosage treatment[14].
CTLs migration to tumor site is a key limiting factor to adoptive
cell therapy efficacy. We have recently shown that CD137 is
expressed on tumor endothelial cells. Ligation of CD137 on tumor
endothelium unleashes a pro-inflammatory switch that promotes
the entry of CTLs inside the tumor[7]. In this regard, CD137
monoclonal antibody (mAb) enhances T cell migration and
cytotoxic activity.
The agent based model derived in this work is first tuned to
reproduce the available in vivo results. After this tuning phase it is
used to predict the role of CD137 on endothelial cells. This is an
important step in the area of melanoma treatment as currently there
is no animal model available to fully isolate the role of CD137 on
endothelial cells in tumor rejection after immunotherapy.
Results and Discussion
We analyzed six pre-clinical cases of B16-OVA melanoma
treatment in immunocompetent mice, namely: i) Control, i.e.
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mice that received no treatment; ii) Anti-CD137, i.e. mice that
received i.p. 100 ug of anti-CD137 monoclonal antibody; iii) Non
activated OT-1, i.e. mice treated with 26106 antigen naı¨ve OT-
1-T cells i.v.; iv) Anti-CD137+Non activated OT-1, i.e. mice
that got i.p. 100 ug of anti-CD137 monoclonal antibody and i.v.
26106 naı¨ve OT-1-T cells; v) Activated OT1, i.e. mice that
received 26106 antigen activated OT-1-T cells i.v.; vi) Anti-
CD137+Activated OT-1, i.e. mice that got i.p. 100 ug of anti-
CD137 monoclonal antibody and i.v. 26106 activated OT-1-T
cells.
We performed 100 in silico experiments for each of the five
treated cases plus 100 for the untreated case. Time zero of the
simulation corresponds to a 6–8 weeks old mouse. The simulation
ends at day 33 post-tumor injection.
Figure 1 and Figure 2 show the tumor growth for the six cases in
the in vivo and in the in silico experiments, respectively.
A comparison with Figure 1 shows excellent agreement with in
vivo experiments. Substantially, in the in vivo experiments we don’t
observe any significant difference among control, treated with
Anti-CD137 mAb and treated with non activated OT-1 mice: the
tumor growth is not affected at all. Looking at the correspondent
curves in Figure 2, we find the same tumor growth dynamics.
Looking at the cases of mice treated with activated OT-1 T cells
and resting OT-1 + Anti-CD137 we observe a light reduction of
the tumor area (as reported perfectly also in the in silico curves), but
the tumor growth velocities are not affected. Finally in the mice
treated with activated OT-1 T cells + Anti-CD137 mAb the tumor
is almost totally rejected by day 20. Even in this case, simulations
show an excellent agreement with in vivo data.
Figure 3 shows four phases of tumor growth dynamics in a
typical simulation of an untreated mouse. It depicts the tumor
growth as spatial distribution of cancer cells in the simulated
portion of mouse tissue. In this case, TC cells are almost unable to
infiltrate into the core of the tumor. If we compare this situation
with the one showed by Figure 4, we note that in this case, thanks
to the effect of anti-CD137 mAb, OT-1 T cells are able to
infiltrate the tumor core, and finally destroy cancer cells (Figure 5).
The simulation is then able to capture the major effect of anti-
CD137, i.e. the augment of the cytotoxicity of TC cells and the
ability to follow chemotaxis gradients and consequently to
infiltrate the tumor (Figure 6).
In a different experiment, we started treatment with OT-1
activated T cells or OT-1 activated T cells + Anti-CD137 mAb at
day 8 after tumor inoculation. Figure 7A displays the results for the
in vivo experiment. When treatment is initiated at the indicated
time, the combined therapy is completely ineffective, suggesting a
Figure 1. The conceptual model. This figure conceptually explains the biological workflow. It represents the first step for successfully modeling
the scenario. Arrows represent the logical flow. Labels explain the interactions or the actions (i.e., status change, activities and functions) by the
involved entities.
doi:10.1371/journal.pone.0026523.g001
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relatively reduced tumor T cell infiltration capable of eradicating
B16-OVA melanoma. In silico experiments nicely reproduce the in
vivo experimental results. Our computational model is able to
capture the underlying dynamics of combined immunotherapy in
two different experimental scenarios that include 9 different
treatment options.
Model predictions
We have previously shown that CD137 is expressed on tumor
endothelial cells[7]. CD137 activation with agonist monoclonal
antibodies on tumor endothelial cells up regulates adhesion
molecules and promotes T cell infiltration inside tumors.
Currently, there is no animal model available to fully isolate
the role of CD137 on endothelial cells in tumor rejection after
immunotherapy. Such animal model, CD137 conditional
knockout on endothelial cells can be simulated using the agent
based model described in this work. Combined immunotherapy
under the same conditions as described in Figure 3 does not
eliminate B16-OVA in mice that do not express CD137 on
endothelium (Figure 8A). CD8 T cell infiltration is drastically
reduced and delayed in time compared to wild type in silico mice
(Figure 8B). Entrance of killer T cells at late time points is
ineffective to eliminate a tumor burden beyond 1 cm in
diameter. Therefore early infiltration of T cells that seems to
be dependent on CD137 expression on tumor vasculature is
predicted as an important factor to dictate the therapeutic
results. Although the predictions for endothelium CD137
involvement in therapy are of much interest, clearly demand
confirmatory experimental verification. However, previous
experimental results are fully compatible with this hypothe-
sis[7,8,22].
Figure 2. Activated OT-1 cells and systemic injection of anti-CD137 mAb show therapeutic synergy against B16-OVA melanoma.
Mice were subcutaneously implanted with B16-OVA cells on day 0 and treated on day 3 with 100 mg of rat IgG (control) or anti-CD137 mAb i.p. Mice
also received on the same day activated or resting OT-1 cells i.v.
doi:10.1371/journal.pone.0026523.g002
Figure 3. Tumor-area curves of virtual mice receiving OT-1 T cells and anti-CD137 mAb. B16-OVA cells were injected toward the
immediate neighborhood in the center of lattice at timestep 0. Immunotherapy on day 3 with 100 mg of rat IgG (control) or anti-CD137 mAb i.p. were
simulated injecting the compound around the lattice walls. Virtual mice that also received in the same day activated or resting OT-1 T cells i.v. were
simulated in the same way.
doi:10.1371/journal.pone.0026523.g003
SimB16
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For cost-effectiveness analysis one can estimate that each group
of six mice (as those shown in the present paper) developing
tumors and being treated takes around 600-800 $ taking into
account: per mouse cost, animal facility personnel, investigator
time, treatment cost (T cells+antibodies). Typical experiments
would cost about 1,800–2000$. Having this estimation in mind, it
is clear that an in silico approach can save both money and time,
suggesting target experiments and then minimizing the number of
needed experiments.
Biological data availability has grown enormously in the past
two decades. Such a large amount of data requires a computa-
tional and logical framework to be organized and analyzed.
In this scenario, computational models are powerful tools for
knowledge discovery both for biological and medical sciences. To
achieve this goal, one needs both descriptive and predictive
computational models. A descriptive model reproduces in silico
results obtained from wet laboratory experiments or clinical
treatment. If a predictive model is able to forecast the outcome of
Figure 4. In silico tumor growth dynamics in a typical simulation of an untreated mouse. From upper-left, following clock-wise way,
cancer cells dynamics at day 7, 14, 21, 28 following tumor cell inoculation.
doi:10.1371/journal.pone.0026523.g004
SimB16
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new possible experiments or treatments and this model capability
is verified by a new experiment or independent clinical data, then
it can be used as predictive model. Then the model can be used to
forecast in silico, with much less cost and effort, the outcome of
many bio-experiments or clinical trials and rank them according to
the quality of their results. Only the best experimental condition
will be tested in vivo saving money, time and animal distress. As it is
well known, models improve in the virtuous cycle of experiment –
model – experiment widely used in the physical sciences.
In this paper we presented a model to analyze the co-
stimulatory effect of anti-CD137 mAb for the melanoma treat-
ment upon synergistic adoptive transfer of activated OT-1 T cells.
The reported in vivo show that a single administration of anti-
CD137 mAb plus activated OT-1 T cells is sufficient to completely
reject the B16-OVA, while single components or not activated
OT-1 T cells have no success.
The in silico experiments performed with the presented
computational model show very good agreement with their in vivo
counterpart. The model has been then used to identify the role of
CD137 on endothelial cells in tumor rejection after immunother-
apy, as currently there is no animal model to conduct these kind of
experiments. The model predicts that early infiltration of T cells
seems to be dependent on CD137 expression on tumor
vasculature. These predictions clearly demand confirmatory
experimental verification; however, previous experimental results
are fully compatible with this hypothesis.
Many aspects of CD137 molecule biology are still not fully
understood. Investigating these aspects requires many difficult and
expensive wet lab experiments. Our ongoing goal is to test the
predictive ability of the model with few illustrating scenarios and
then use the model as a virtual lab to analyze different aspects and
hypotheses regarding this mode of immunotherapy. This work is
still in progress and results will be published in due course.
Materials and Methods
The biological scenario in which the B16-OVA melanoma and
the related induced immune response operate, need to be
described in a rationale manner, before they can be translated
into a mathematical/computational description. This means that
the description must be able to capture the essential properties of
the phenomenon i.e., the system entities, their organization and
their dynamic behavior.
The role of a conceptual model is then to drive biological
knowledge into a solvable mathematical representation, offering a
conceptual framework for iterative thinking about the scientific
domain allowing the inclusion of additional properties in the same
scheme with a limited effort.
To satisfy the above properties, the first task in building a solid
conceptual model is to identify all the relevant entities and their
properties (cells, molecules, adjuvants, cytokines, interactions) that
biologists and clinicians recognize as crucial in the in vivo scenario.
Next, the modeler has to categorize all the interactions among
entities that play a relevant role. These must be described using
biological knowledge inside a logical framework, to be able, as a
further step, to map them from the biological world to a
mathematical/computational one. The final step is to set all the
biological constants, relevant functions, and identify the best
computational framework capable of hosting the simulated
biological scenario.
Having all the above described steps in mind, the first task to
deal with is the choice of the entities we have to include in the
model. We considered both cellular and molecular entities.
We considered both B lymphocytes and T lymphocytes. Plasma
B cells (P) were inserted as specific antibodies producers. Both
cytotoxic T cells (TCs) and helper T cells (TH) were inserted in the
model. Monocytes are represented as well and we take care of
macrophages (M). Dendritic cells play the role of cross-
presentation antigen processing cells. Two major types of dendritic
cells have been discovered and have been named conventional
(cDCs) and plasmacytoid dendritic cells (pDCs). pDCs are not able
to present the antigen, so we represented only cDCs in the model,
along with their specific capability of processing and cross-
presenting antigen peptides both in MHC class I and MHC class
II molecules. Immune complexes (ICs) were also inserted in the
model and treated as antibody-tumor antigen complex[15].
Several molecules entities engage an important role in
simulating the B16-OVA melanoma biological scenario. The
model distinguishes between simple small molecules like interleu-
kins or signaling molecules in general and more complex
molecules like immunoglobulins and antigens, for which we need
to represent the specificity. Regarding the interleukin class
molecules, we represent interleukin 2 (IL-2) that is necessary for
the development of T cell immunologic memory, one of the
unique characteristics of the immune system, which depends upon
the expansion of the number and function of antigen-selected T
cell clones.
Immunoglobulins of class IgG are represented as well. There is
no immunoglobulins class switching representation, because we
don’t need to represent other classes of Ig and because IgG is the
most versatile immunoglobulin since it is capable of carrying out
all of the functions of immunoglobulins molecules. Moreover IgG
is the major immunoglobulin in serum (75% of serum Ig is IgG)
and IgG is the major Ig in extra vascular spaces.
The model also contains dominant characteristics of the OT-1
transgenic mice that were used in in vivo experiments, i.e.:
N all CD8 single positive T cells in the thymus express the
transgenic TCR that is specific for OVA peptide in the context
of H2-Kb;
N the CD8 single positive T cells in the thymus express high
levels of the transgenic TCR;
N increased CD8-positive T cell number respect to CD4-positive
(7-fold reduction of CD4-positive)
N CD8 T cells have high cytolytic activity toward target cells
containing OVA peptide.
A detailed overview of the conceptual model is shown in Fig. 1.
The biological dynamics of the cells is realized by state-changes:
each cellular entity is labeled by a suitable state that describes its
current biological condition (naı¨ve, activated, duplicating and so
on). The state can change when a cell interacts with another cell,
with a molecule or with both of them.
Next step is to identify the relevant interactions that happen
during the induced immune response against B16 melanoma. We
included the following interactions.
N B lymphocyte and helper T lymphocyte interaction. If the T receptor
(CD4) at the surface of a T helper lymphocyte binds
specifically peptide/major histocompatibility complex class II
Figure 5. Cytotoxic T cells dynamics.With the anti-CD137 stimulation, TC cells are able to infiltrate tumor and consequently they kill cancer cells,
causing total rejection of B16- melanoma. From upper-left, following clock-wise way, OT-1 cells dynamics at day 7, 14, 16, 20, 24, 28.
doi:10.1371/journal.pone.0026523.g005
SimB16
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at the surface of the antigen presenting B lymphocyte, helper T
lymphocyte proliferates and secretes interleukin 2. At the same
time, B lymphocyte proliferates and differentiates into a
plasma cell.
N Macrophage and helper T lymphocyte interaction. If a T cell receptor
(CD4) at the surface of T helper lymphocyte binds specifically
peptide/major histocompatibility complex class II at the
surface of antigen processing macrophage cell, helper T
lymphocyte proliferates and secretes interleukin 2.
N Dendritic cell with B16 melanoma tumor associated antigen. If a cDC
encounters a B16 melanoma tumor associated antigen, the
cDC internalizes the antigen and processes it into peptides that
are then presented by major histocompatibility complex class
II or by major histocompatibility complex class I (cross-
presentation ability of cDCs) at the dendritic cell surface. cDC
becomes antigen presenting cell.
N Cytotoxic T cell with antigen presenting cDC interaction. If a T cell
receptor (CD8) at the surface of cytotoxic T lymphocyte binds
specifically peptide/major histocompatibility complex class I at
the surface of antigen processing dendritic cell, cytotoxic T
lymphocyte begins activated (primed).
N Cytotoxic T cell with B16-OVA melanoma cell interaction. If the T cell
receptor at the surface of an activated T cytotoxic lymphocyte
binds specifically peptide/major histocompatibility class I at
the surface of B16-OVA melanoma cell, in presence of IL-2
and anti-CD137 the TC kills B16-OVA melanoma cell.
Figure 6. In silico tumor growth dynamics in a typical simulation of a mouse treated with activated OT-1 cells and anti-CD137. From
upper-left, following clock-wise way, OT-1 cells dynamics at day 7, 14, 16, 20, 24, 28.
doi:10.1371/journal.pone.0026523.g006
Figure 7. Combined treatment started at day 8 is not effective
to eliminate B!6 melanoma. A. In vivo experiment. Mice were
subcutaneously implanted with B16-OVA cells on day 0 and treated on
day 8 with 100 mg of rat IgG (control) or anti-CD137 mAb i.p. Mice also
received on the same day activated or resting OT-1 cells i.v. B. In silico
experiment. B16-OVA cells were injected toward the immediate
neighborhood in the center of lattice at timestep 0. Immunotherapy on
day 8 with 100 mg of rat IgG (control) or anti-CD137 mAb i.p. were
simulated injecting the compound around the lattice walls. Virtual mice
that also received in the same day activated or resting OT-1 T cells i.v.
were simulated in the same way.
doi:10.1371/journal.pone.0026523.g007
Figure 8. Model prediction. CD137 expression on endothelial cells is
essential for tumor rejection. A. In silico experiment. WT or CD137
KO (only on endothelial cells) virtual mice were treated as in Figure 3. B.
CD8 T cell infiltration after combined therapy in WT and or CD137 KO
virtual mice.
doi:10.1371/journal.pone.0026523.g008
SimB16
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N Anti-CD137 with activated cytotoxic T cell. Anti-CD137 will
improve cytotoxicity, duplication rate and chemotaxis sensi-
tivity of activated cytotoxic T cell.
The model takes into consideration a 2D domain physical space
with periodic boundaries. Apparently this seems a limitation in
terms of space representation. On the other hand we know that all
the processes and interactions of the simulated scenario take place
in an epithelium tract and in the surrounding lymph nodes. Hence
this is a good approximation and gives to the model implemen-
tation improvements in both speed and simplicity.
As all the entities and the interactions have been identified and
conceptually introduced, one has to deal with the final step of the
modeling process i.e., the choice of the more suitable modeling
technique.
Using our previous experiences in the field of simulation of
different pathologies and the related immune system response [16–
18,24–28], we choose to adopt an agent based modeling (ABM)
approach as a computational framework.
Although ABM is not subject to a deep analytical analysis by
presently known methods, it has many advantages.
The ABM is stochastic, so it is possible to estimate the
distribution of behaviors exhibited by the entire system, not just
the average, in fact determinism is avoided and it is possible to take
into account the effect of the spatial distribution easily.
The ABM is also able to accurately represent many of the
biological processes of interest so that the approximations in the
model are usually more biological in character than mathematical.
Moreover it is possible to approaching nonlinearities in as
simple way because they are not intrinsically hard to handle. This
also means that it is possible to add complexity or modify the
model without introducing any new difficulties in solving it.
Most mathematical models of the immune response are
deterministic and use, for example, differential equations (solved
by numerical integration) to model the biological interactions
among cells and molecules. However, the assumptions made by
the deterministic method do not hold for many processes that are
sensitive to the behavior of a relatively small number of entities.
Another problem of equations is given by their formalism. The
‘‘language’’ used by equations is not usually known to biologists,
making the communication with mathematicians/Computer
scientists even more hard and damaging the interdisciplinary
collaboration for any model to be built [23].
This method is also intrinsically numerically stable thanks to the
fact that most of the variables representing the attributes of the
entities are integers and very few floating point operations are
required. Modeling the immune system response with a differen-
tial equation model, trying to represent all the immunological
aspects modeled by the ABM, is discouraging. To justify this
statement consider that to coherently model the immune system it
is fundamental to take into account entities receptors variability.
Receptors variability can reach approximately 107 different
receptors at the same time in the host (from a range of 1013 2
1015 possible receptors) and, even modeling a smaller receptor
range (i.e. 103 2 106), it can represent a problem.
To model, for example, the clonal selection process problem
with an ODE, one should take into account a number of equations
that is of the same order of the allowed receptors variability.
Moreover presentation or stimulation processes involve different
types of specialized cells, so the number of equations grows further.
Imagine a typical process of the immune system, i.e. when an
cell A, after an interaction with a cell B, switches its internal state
and mutates into a new cell C (for example a B lymphocyte that
differentiates into a plasma cell after stimulation by a TH
lymphocyte).
Let R be the allowed set of possible receptors, Ai be the set of
entities of type A with receptor i M R and Ci be the set of entities of
type C with receptor i M R (even if affinity maturation occurs in
real immune system, we suppose for simplicity that the receptor
does not change during the switch).
The Ai cells can hypothetically interact with all Bj , j = 1...|R|,
and the stimulation depends by the affinity between receptors i
and j, so one has:
dCi tð Þ
dt
~
XR
j~1
AiBjKijz . . .
where kij represents the affinity ratio between the receptors i and j
and i, j = {1, . . . , |R|}. This differential equation has to be
repeated for all the A clones (one for each different receptor i,
i M R).
If the biological problem is not homogeneous in space, the use
of a density function f (t, x) should be required for every population
(i.e. a partial differential equations system), further increasing the
complexity of the model.
Moreover immune system interactions and events are not
deterministic. This means that one should include a source of
randomness into the equations. Stochastic differential equations
(SDE) or stochastic partial differential equations (SPDE) should be
then used.
Summarizing, if R is allowed receptor variability (i.e. 212 in
SimB16) and S the number of different kinds of entities with
specialized receptors (i.e. S = 3 for B, TC and TH representation,
forgetting about plasmacells, antibodies, antigens and entities
state-changes), a system of (at least) R ? S ( = 3 ? 212 < 104)
stochastic partial differential equations (with various non-lineari-
ties) has to be used to tackle the biological problem in a similar way
the CS automaton does.
Model implementation: SimB16 simulator
The computer implementation of the model (SimB16 hereafter)
has three main classes of parameters: i) values known from
standard immunology literature; ii) parameters strictly correlated
with the specific biological scenario we want to simulate, i.e.
parameters that measure the B16-OVA melanoma dynamics, its
behavior and its interactions with the immune system of the host;
iii) parameters with unknown values which we set to plausible
values after performing a series of systematic tests.
Table 1 details the values of the parameters retrieved from the
literature. Table 2 shows specific parameters of B16-OVA
melanoma.
SimB16 has set of free parameters that can be used to tune the
model results with experimental data. The list of these parameters
and their final used values are quoted in Table 3. Tuning
parameters were initially set using previous modeling experience
and then adjusted to reproduce experimental behavior. The first
parameter we set is nbit_str that determines the repertoire size. It
indicates the number of bits used to represent the molecules and
the cells binding sites like cell receptors and antigen peptides and
epitopes. It was set to 12 corresponding to a potential repertoire of
4096 cell receptors. This is obviously very poor respect to the real
immunological repertoire, but it was sufficient to capture the
global behavior of the B16-OVA/immunotherapy process. The
parameter min_match specifies the minimal number of matching
bits that are required to have a non-zero probability to bind;
affinity_level is the probability to interact between two binding sites
SimB16
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whose match is min_match; max_lfact regulates the probability for
a cell that is duplicating to create a new cell; IL2_eff is a factor
expressing the efficiency of interleukin-2 in stimulating growth of
the lynphocytes; thymus_eff represents the efficiency of the thymus
in selecting non self-reactive thymocytes. In general the fraction of
circulating auto-reactive TH cells should be below 0.1%.
In order to catch the evolution of all quantities, the time step of
a simulation must be lesser than all characteristics times. We chose
a time step of 8 hours to satisfy this requirement.
Parameter hyper_mut is the per-bit mutation probability for the
antibodies. The hyper-mutation rate of antibodies is taken as the
suggested value in Celada, 1996; plasma_rel controls the quantity of
specific IgG antibodies released by a plasma B cell per time step;
prob_M_Ag is the probability for a macrophage to phagocyte/
internalize an antigen; prob_M_IC is the probability for a
macrophage to phagocyte an immune complex; prob_cDC_Ag is
the probability for a dendritic cell to phagocyte/internalize an
antigen. This was set to a higher level than the prob_M_Ag as DC
are known to be better antigen presenting cells; B_dup is the
number of time steps a B cells creates a copy of itself when
duplicating; TH_dup is the number of time steps a TH cells creates
a copy of itself when duplicating; TC_dup is the number of time
steps a TH cells creates a copy of itself when duplicating.
With these settings, the model showed a good robustness, giving
reasonable output. This means that if we slightly change
parameters such as the initial leukocyte formula, the half life of
entities, and so on, the model consistently varies its results, without
biological discrepancy when compared with available experimen-
tal data retrieved from the above cited literature.
SimB16 takes care of the main immune system functions and
peculiar characteristics, such as diversity of specific elements, major
histocompatibility classes restriction, clonal selection by antigen
affinity, thymus education of T cells, antigen processing and
presentation (both the cytosolic and endocytic pathways are
implemented), cell-cell cooperation, homeostasis of cells created by
the bone marrow, hypermutation of antibodies, cellular and humoral
response and immune memory. Receptors, ligands and immune
system specificity are implemented in SimB16 by a bit-string polyclonal
lattice method. This was well-described method and the interested
reader can found additional information in specific literature [19].
Immune system entities interact both each other and with the
cells and molecules of the body. From the point of view of biology,
an interaction is a complex event that includes chemical, biological
and dynamical actions. We implemented both recognition phase
and affinity eventually enhanced by adjuvants. When two entities,
which may interact, lie in the same lattice site then they interact
with a probabilistic law. All entities that may interact and are in
the same site have a positive interaction.
Physical proximity is modeled through the concept of lattice-
site. All interactions among cells and molecules take place within a
lattice-site in a single time step, so that there is no correlation
between entities residing on different sites at a fixed time.
The simulation space is represented as an L6L hexagonal (or
triangular) lattice (six neighbors), with periodic boundary conditions
to the left and right side, while the top and bottom are represented by
rigid walls. All entities are allowed to move with uniform probability
between neighboring lattices in the grid with equal diffusion
coefficient. We considered 3600 mm2 (60 mm660 mm) of mouse
tissue that we simulated using a lattice grid size of 9466946.
Compared to the complexity of the real biological scenario, the
model can be extended in many aspects. On the other hand the
model is complete enough and is able to describe the major aspects
of the modeled experiment.
In order to model the melanoma growth pattern, we followed
the procedure described hereinafter. The first step to accomplish is
Table 2. SimB16 parameters with known values retrieved
from specific literature.
Entity Initial quantity (per mL) Half life
B16 cancer cells 0 10 years
Anti-CD137 N/A 23 days
OT-1 T-cells N/A 3.3 days
N/A means not applicable.
doi:10.1371/journal.pone.0026523.t002
Table 1. SimB16 parameters with known values retrieved
from immune system specific literature.
Entity Initial quantity (per mL) Half life
B 260 3.3 days
TH 200 3.3 days
TC 434 3.3 days
cDC 351 3.3 days
M 351 3.3 days
EP 351 3.3 days
NK 351 3.3 days
P 0 3.3 days
IC 0 4.0 days
IL-2 0 1.6 days
CA 0 1.6 days
IgG 0 23.0 days
CA stands for Chemo-Attractans.
doi:10.1371/journal.pone.0026523.t001
Table 3. SimB16 tuning parameters.
Parameter Value
Timestep 8 hours
hyper_mut 1024 in 8 hours
plasma_rel 10 ng/m per 8 hours
prob_M_Ag 1022 in 8 hours
prob_M_IC 1021 in 8 hours
prob_cDC_Ag 261022 in 8 hours
B_dup 16
TH_dup 16
TC_dup 16
nbit_str 12
min_match 9
affinity_level 561022
max_lfact 5
IL2_eff 100%
thym_eff 99.9%
doi:10.1371/journal.pone.0026523.t003
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to keep track of the temporal evolution of the cancer in absence of
any treatment. To this end the diameter of melanomas for
untreated mice has been measured and stored at different times
during the experiment.
Supposing a disk-shaped layout for the melanoma and having
knowledge of the mean diameter of melanoma cancer cells, we
estimated the number of cancer cells (in the observed melanomas)
for all the measurements made.
This data has been used with a curve fitting procedure to
estimate the unknown parameters needed to model the cancer
growth kinetics under the hypothesis that the melanoma growth
followed a Gompertz law[20].
The law, which is commonly considered suitable for describing
populations growths, uses two factors: a growth factor that
decreases in time and a constant mortality factor. Thanks to the
growth factor deceleration, the dimension of the population tends
asymptotically to a certain threshold (carrying capacity) giving a
sigmoid shape to the law.
Once the unknowns of the growth law have been determined,
they can be used to reproduce the growth kinetics in time of the
melanoma. In particular, we approximate the differential form of
the Gompertz law with the forward Euler discretization method,
obtaining:
w~xtz1{xt~Dt(xt(a{b:ln(xt)))
where xt and xt+1 are the number of cancer cells at time t and t+1, a
and b are the fitted unknowns of the growth law, and Dt = 1 since the
simulator uses discrete time-steps. Starting from time-step 0, where
it is supposed x0 = 200000 (we suppose that nearly 60% of the
injected cancer cells die before to settle and duplicate), the model
determines at each time-step t the expected number of newborn
cancer cells w (= xt+12 xt) that will be introduced into the simulation
at time-step t+1 on the basis of the actual number of cancer cells xt.
Chemotaxis is a biological phenomenon in which some cells,
like immune system cells, direct their movements according to
certain chemical signals. Chemotaxis is a very complex process
involving many factors such as short and long range interactions
and no model is probably able to completely represent this
phenomenon, since it has not yet fully understood[21].
In a first attempt to mimic short range chemotaxis effects,
higher probabilities of being chosen are given to sites containing
chemoattractans released by endothelial cells, activated macro-
phages and activated OT-1 cells.
In vivo experimental settings
Immunotherapy setting. B16 melanoma cell line was
derived from an aggressive spontaneous melanoma in pure
C57BL6 and B16F10 was derived as a clonal variant from a
lung metastasis of this cell line. B16-OVA was transduced with the
chicken ovalbumin gene to use it as a model tumor antigen. In
tumor immunology these variants are considered poorly
immunogenic in the sense that immune-mediated rejections or
growth retardations are difficult to achieve.
The experimental setup is oriented to model therapeutic
synergy between anti-CD137 monoclonal antibodies and adoptive
T cell therapy in melanoma. B16-OVA is a poorly immunogenic
murine tumor that does respond to neither anti-CD137 mAb nor
adoptive transfer used as monotherapy. The treatment protocol
includes a single injection of anti-CD137 mAb and adoptive T cell
transfer of OVA specific TCR-transgenic CD8 T cells.
Cell lines. B16-OVA was obtained and authenticated from
ATCC. Cells were cultured in complete RPMI medium (RPMI
1640 with Glutamax [Gibco, Invitrogen, CA] containing 10%
heat-inactivated FBS (SIGMA-ALDRICH, UK), 100 IU/ml peni-
cillin and 100mg/ml streptomycin (Biowhittaker, Walkersville,
MD) and 50 mM 2-mercaptoethanol.[Gibco]). B16-OVA was
cultured under G418 selection (1 mg/mL, Gibco).
Mice. C57 BL/6 female mice (6–8 weeks old) were purchased
from Harlan Laboratories (Barcelona, Spain). OT-I TCR-transgenic
mice were from The Jackson Laboratory (Barcelona, Spain) and
bred in our animal facility under specific pathogen-free conditions.
Animal procedures were conducted under institutional guidelines
that comply with national laws and policies (study 066/10).
Antibodies. Anti-CD137 mAb is produced from the 2A
hybridoma, kindly provided by Dr. Lieping Chen. The mAb
produced by this hybridoma was purified from culture supernatant
by affinity chromatography in sepharose protein G columns (GE
Healthcare Bio-sciences AB, Uppsala, Sweden) dialized and
quality controlled including determinations of lipopolysaccharide
(LPS) concentration (Antibody BCN, Barcelona, Spain, as a
contractor). Control IgG from rat serum was obtained from
Sigma-Aldrich.
In vivo tumor growth and treatment. 0.56106 B16-OVA
cells were injected in 100 mL PBS subcutaneously in the right flank
of C57 BL/6 mice. OT-1 T cells were prepared from the spleens of
OT-I TCR transgenic mice and activated with 5 ug/mL of
OVA257-264 peptide (NeoMPS, Strasbourg, France) for 48 hours
at 37uC in 5% CO2 and washed extensively before i.v. inoculation.
On day 3 or 8 after tumor injection mice received i.p. 100 ug of
anti-CD137 monoclonal antibody or control rat IgG and 26106
activated or naive OT-1T cells i.v. Tumor growth was evaluated by
measuring 2 perpendicular diameters with a digital caliper every 3–
4 days. Mice were sacrificed when tumor sizes reached 450 mm2.
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